Pathstone Family Office’s Globus Medical GMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$613K Buy
12,341
+2,914
+31% +$163K ﹤0.01% 944
2023
Q2
$563K Buy
9,427
+519
+6% +$29.6K 0.01% 706
2023
Q1
$503K Sell
8,908
-2,633
-23% -$169K 0.01% 695
2022
Q4
$276K Buy
11,541
+1,500
+15% +$102K 0.01% 960
2022
Q3
$598K Buy
10,041
+2,845
+40% +$171K 0.01% 586
2022
Q2
$404K Sell
7,196
-4,817
-40% -$317K 0.01% 666
2022
Q1
$885K Buy
+12,013
New +$835K 0.02% 358
2021
Q1
– Sell
-12
Closed -$1K – 932
2020
Q4
$1K Hold
12
– – ﹤0.01% 1088
2020
Q3
$1K Sell
12
-12
-50% -$619 ﹤0.01% 738
2020
Q2
$2K Buy
+24
New +$1.16K ﹤0.01% 627

Other funds holding GMED

Pathstone Family Office's GMED Position: Q3 2023 in Review

Pathstone Family Office increased its Globus Medical (GMED) stake by 31% in Q3 2023, buying an estimated $163K and bringing the position to 12,341 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Pathstone Family Office first reported a position in GMED in Q2 2020 and has held it in 10 quarters since. The position peaked at $885K in Q1 2022. 430 funds tracked by Wall St. Rank hold GMED as of Q3 2023.

  • Pathstone Family Office held 12,341 shares of Globus Medical worth $613K as of Q3 2023.
  • Pathstone Family Office bought 2,914 Globus Medical shares in Q3 2023, an estimated $163K.
  • Globus Medical made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #944 holding.
  • Pathstone Family Office first reported a position in Globus Medical in Q2 2020 and has held it in 10 quarters since.
  • Pathstone Family Office's Globus Medical position peaked at $885K in Q1 2022.
  • 430 funds tracked by Wall St. Rank held Globus Medical as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.